GPCM
NMTR

Granite Point Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

Granite Point Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-54,351
Closed -$623K – 195
2020
Q2 		$623K Buy
+54,351
New +$613K 0.03% 124
2019
Q2 		– Sell
-21,459
Closed -$828K – 117
2019
Q1 		$828K Buy
+21,459
New +$928K 0.08% 71

Other funds holding NMTR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Granite Point Capital Management's NMTR Position: Q3 2020 in Review

Granite Point Capital Management sold out of 9 Meters Biopharma (NMTR) in Q3 2020, closing a stake of 54,351 shares — an estimated $623K sold.

Granite Point Capital Management first reported a position in NMTR in Q1 2019 and held it in 2 quarters. The position peaked at $828K in Q1 2019. 42 funds tracked by Wall St. Rank hold NMTR as of Q3 2020.

  • Granite Point Capital Management reported no remaining 9 Meters Biopharma position as of Q3 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 54,351 9 Meters Biopharma shares in Q3 2020, an estimated $623K.
  • Granite Point Capital Management first reported a position in 9 Meters Biopharma in Q1 2019 and held it in 2 quarters.
  • Granite Point Capital Management's 9 Meters Biopharma position peaked at $828K in Q1 2019.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2020.

Based on Granite Point Capital Management's 13F filing for Q3 2020, filed 6 Nov 2020.